---
document_datetime: 2025-12-02 05:27:30
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/glidipion.html
document_name: glidipion.html
version: success
processing_time: 0.1231515
conversion_datetime: 2025-12-26 18:57:08.662873
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Glidipion (previously Pioglitazone Actavis Group)

[RSS](/en/individual-human-medicine.xml/66916)

##### Withdrawn

This medicine's authorisation has been withdrawn

pioglitazone Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 19 July 2021, the European Commission withdrew the marketing authorisation for Glidipion (pioglitazone) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Actavis Group PTC ehf, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Glidipion was granted marketing authorisation in the EU on 15 March 2012 for treatment of type 2 diabetes mellitus. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2016. The product has not been marketed in the EU.

Glidipion is a generic medicine of Actos. There are other generic medicinal products of Actos authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Glidipion is updated to indicate that the marketing authorisation is no longer valid.

Glidipion : EPAR - Summary for the public

English (EN) (636.27 KB - PDF)

**First published:** 26/04/2012

**Last updated:** 17/10/2022

[View](/en/documents/overview/glidipion-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-375)

български (BG) (806.52 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/bg/documents/overview/glidipion-epar-summary-public_bg.pdf)

español (ES) (694.26 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/es/documents/overview/glidipion-epar-summary-public_es.pdf)

čeština (CS) (776.09 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/cs/documents/overview/glidipion-epar-summary-public_cs.pdf)

dansk (DA) (700.24 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/da/documents/overview/glidipion-epar-summary-public_da.pdf)

Deutsch (DE) (698.92 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/de/documents/overview/glidipion-epar-summary-public_de.pdf)

eesti keel (ET) (695.29 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/et/documents/overview/glidipion-epar-summary-public_et.pdf)

ελληνικά (EL) (833.98 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/el/documents/overview/glidipion-epar-summary-public_el.pdf)

français (FR) (700.15 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/fr/documents/overview/glidipion-epar-summary-public_fr.pdf)

italiano (IT) (700.65 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/it/documents/overview/glidipion-epar-summary-public_it.pdf)

latviešu valoda (LV) (697.82 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/lv/documents/overview/glidipion-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (720.32 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/lt/documents/overview/glidipion-epar-summary-public_lt.pdf)

magyar (HU) (767.3 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/hu/documents/overview/glidipion-epar-summary-public_hu.pdf)

Malti (MT) (695.29 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/mt/documents/overview/glidipion-epar-summary-public_mt.pdf)

Nederlands (NL) (699.7 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/nl/documents/overview/glidipion-epar-summary-public_nl.pdf)

polski (PL) (773.96 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/pl/documents/overview/glidipion-epar-summary-public_pl.pdf)

português (PT) (699 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/pt/documents/overview/glidipion-epar-summary-public_pt.pdf)

română (RO) (664.4 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/ro/documents/overview/glidipion-epar-summary-public_ro.pdf)

slovenčina (SK) (752.96 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/sk/documents/overview/glidipion-epar-summary-public_sk.pdf)

slovenščina (SL) (766.92 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/sl/documents/overview/glidipion-epar-summary-public_sl.pdf)

Suomi (FI) (695.99 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/fi/documents/overview/glidipion-epar-summary-public_fi.pdf)

svenska (SV) (697.07 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/sv/documents/overview/glidipion-epar-summary-public_sv.pdf)

Glidipion : EPAR - Risk-management-plan summary

English (EN) (619.62 KB - PDF)

**First published:** 20/07/2020

**Last updated:** 17/10/2022

[View](/en/documents/rmp-summary/glidipion-epar-risk-management-plan-summary_en.pdf)

## Product information

Glidipion : EPAR - Product Information

English (EN) (1 MB - PDF)

**First published:** 26/04/2012

**Last updated:** 17/10/2022

[View](/en/documents/product-information/glidipion-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-314)

български (BG) (2.09 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/bg/documents/product-information/glidipion-epar-product-information_bg.pdf)

español (ES) (1.17 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/es/documents/product-information/glidipion-epar-product-information_es.pdf)

čeština (CS) (1.97 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/cs/documents/product-information/glidipion-epar-product-information_cs.pdf)

dansk (DA) (1.19 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/da/documents/product-information/glidipion-epar-product-information_da.pdf)

Deutsch (DE) (1.14 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/de/documents/product-information/glidipion-epar-product-information_de.pdf)

eesti keel (ET) (1.04 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/et/documents/product-information/glidipion-epar-product-information_et.pdf)

ελληνικά (EL) (2.19 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/el/documents/product-information/glidipion-epar-product-information_el.pdf)

français (FR) (1.16 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/fr/documents/product-information/glidipion-epar-product-information_fr.pdf)

hrvatski (HR) (1.22 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/hr/documents/product-information/glidipion-epar-product-information_hr.pdf)

íslenska (IS) (1.17 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/is/documents/product-information/glidipion-epar-product-information_is.pdf)

italiano (IT) (1.22 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/it/documents/product-information/glidipion-epar-product-information_it.pdf)

latviešu valoda (LV) (1.85 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/lv/documents/product-information/glidipion-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.29 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/lt/documents/product-information/glidipion-epar-product-information_lt.pdf)

magyar (HU) (1.65 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/hu/documents/product-information/glidipion-epar-product-information_hu.pdf)

Malti (MT) (1.89 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/mt/documents/product-information/glidipion-epar-product-information_mt.pdf)

Nederlands (NL) (996.51 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/nl/documents/product-information/glidipion-epar-product-information_nl.pdf)

norsk (NO) (1.22 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/no/documents/product-information/glidipion-epar-product-information_no.pdf)

polski (PL) (1.93 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/pl/documents/product-information/glidipion-epar-product-information_pl.pdf)

português (PT) (1.25 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/pt/documents/product-information/glidipion-epar-product-information_pt.pdf)

română (RO) (1.33 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/ro/documents/product-information/glidipion-epar-product-information_ro.pdf)

slovenčina (SK) (1.87 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/sk/documents/product-information/glidipion-epar-product-information_sk.pdf)

slovenščina (SL) (1.76 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/sl/documents/product-information/glidipion-epar-product-information_sl.pdf)

Suomi (FI) (1.16 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/fi/documents/product-information/glidipion-epar-product-information_fi.pdf)

svenska (SV) (1.15 MB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/sv/documents/product-information/glidipion-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS/1791 11/06/2020

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Glidipion : EPAR - All Authorised presentations

English (EN) (606.29 KB - PDF)

**First published:** 26/04/2012

**Last updated:** 17/10/2022

[View](/en/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_en.pdf)

[Other languages (22)](#file-language-dropdown-290)

български (BG) (631.49 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/bg/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_bg.pdf)

español (ES) (604.7 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/es/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_es.pdf)

dansk (DA) (609.94 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/da/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (610.16 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/de/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (606.62 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/et/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (647.33 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/el/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_el.pdf)

français (FR) (610.62 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/fr/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (606.77 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/is/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_is.pdf)

italiano (IT) (607.2 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/it/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (659.29 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/lv/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (626.79 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/lt/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (647.52 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/hu/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (656.82 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/mt/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (611.38 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/nl/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (606.82 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/no/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_no.pdf)

polski (PL) (630.09 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/pl/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_pl.pdf)

português (PT) (612.19 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/pt/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_pt.pdf)

română (RO) (620.54 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/ro/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (659.39 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/sk/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (622.77 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/sl/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (610.62 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/fi/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (610.36 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/sv/documents/all-authorised-presentations/glidipion-epar-all-authorised-presentations_sv.pdf)

Pioglitazone Actavis Group : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (584.22 KB - PDF)

**First published:** 26/04/2012

**Last updated:** 17/10/2022

[View](/en/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (23)](#file-language-dropdown-330)

български (BG) (664.7 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/bg/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (586.53 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/es/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (635.8 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/cs/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (585.16 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/da/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (585.72 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/de/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (584.74 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/et/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (662.54 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/el/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (585.71 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/fr/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

íslenska (IS) (585.42 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/is/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (585.91 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/it/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (639.73 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/lv/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (604.15 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/lt/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (631.59 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/hu/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (631 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/mt/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (579.74 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/nl/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (579.95 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/no/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (632.76 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/pl/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (577.88 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/pt/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (595.84 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/ro/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (636.53 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/sk/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (624.91 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/sl/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (584.39 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/fi/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (576.87 KB - PDF)

**First published:**

26/04/2012

**Last updated:**

17/10/2022

[View](/sv/documents/conditions-member-states/pioglitazone-actavis-group-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Glidipion (previously Pioglitazone Actavis Group) Active substance pioglitazone hydrochloride International non-proprietary name (INN) or common name pioglitazone Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BG03

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:

- as monotherapy:
    - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;
- as dual oral therapy in combination with:
    - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;
    - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;
- as triple oral therapy in combination with:
    - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.

Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

## Authorisation details

EMA product number EMEA/H/C/002558

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Actavis Group PTC ehf

Dalshraun 1

Marketing authorisation issued 15/03/2012 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Glidipion : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (764.74 KB - PDF)

**First published:** 12/09/2012

**Last updated:** 17/10/2022

[View](/en/documents/procedural-steps-after/glidipion-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Pioglitazone Actavis Group : EPAR - Public assessment report

Adopted

Reference Number: EMA/207946/2012

English (EN) (987.1 KB - PDF)

**First published:** 26/04/2012

**Last updated:** 17/10/2022

[View](/en/documents/assessment-report/pioglitazone-actavis-group-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pioglitazone Actavis Group

Adopted

Reference Number: EMA/CHMP/511503/2011

English (EN) (636.58 KB - PDF)

**First published:** 23/09/2011

**Last updated:** 17/10/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pioglitazone-actavis-group_en.pdf)

**This page was last updated on** 17/10/2022

## Share this page

[Back to top](#main-content)